Mineral Oil Heavy (mineral oil)
Lubricant Laxatives Oral Oil (Ml)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Mineral oil (heavy or light), a complex mixture of hydrocarbons derived from crude petroleum, is a lubricant laxative.
USES: Mineral oil is used to treat constipation. It is known as a lubricant laxative. It works by keeping water in the stool and intestines.
This helps to soften the stool and also makes it easier for stool to pass through the intestines. This medication should not be used by older adults, children younger than 6 years, or by people who are bedridden.
Generic name: mineral oil
Pronunciation: (MIN-er-al oyl)
Drug class: Lubricant Laxatives
Therapeutic class: Gastrointestinal Therapy Agents
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Mineral Oil Heavy
Indications
The following indications are listed for Mineral Oil Heavy:
- Constipation
Dosing
Dosage of mineral oil emulsion is expressed in terms of its mineral oil content. Oral mineral oil preparations should be used only occasionally and should not be administered for longer than 1 week.
The usual oral dosage of mineral oil for adults and children 12 years of age and older is 15-45 mL daily given as a single dose (minimum dose of 15 mL) or in divided doses. For children 6-11 years of age, the usual oral dosage of mineral oil is 5-15 mL daily given as a single dose (minimum of 5 mL) or in divided doses.
Mineral oil enemas are administered rectally in a usual dosage of 120 mL (range: 60-150 mL) daily given as a single dose in adults and children 12 years of age and older and 30-60 mL for children 2-11 years of age.
Mineral oil or mineral oil emulsion is administered orally. Although mineral oil emulsions penetrate and soften fecal material more effectively and are more palatable than plain mineral oil, there appears to be little difference in laxative effectiveness between these two preparations. Mineral oil also may be administered rectally as an enema. Plain (nonemulsified) mineral oil should be administered only at bedtime on an empty stomach. Mineral oil emulsion may be administered with meals. Containers of mineral oil emulsion should be shaken before using.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
Laxatives/Trofinetide
SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
MECHANISM OF ACTION: Trofinetide commonly causes diarrhea of mild to moderate severity. Laxatives may increase the incidence or severity of diarrhea.(1)
CLINICAL EFFECTS: Concurrent use of laxatives with trofinetide may increase the risk of severe diarrhea.(1)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: Patients should stop laxatives before starting trofinetide. If diarrhea occurs, consider anti-diarrheal treatment and monitor hydration status. If severe diarrhea or dehydration occurs, interrupt, reduce dose, or discontinue trofinetide.(1)
DISCUSSION: In clinical trials, 85% of patients on trofinetide developed diarrhea. Concurrent use of laxatives may increase this risk.(1)
Laxatives; Stool Softeners/Tenapanor
SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
MECHANISM OF ACTION: Tenapanor commonly causes diarrhea of mild to moderate severity. Laxatives and stool softeners may increase the incidence or severity of diarrhea.(1)
CLINICAL EFFECTS: Concurrent use of laxatives or stool softeners with tenapanor may increase the risk of severe diarrhea.(1)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: The US manufacturer of tenapanor states that patients should be instructed to avoid stool softeners and laxatives with tenapanor. If severe diarrhea occurs, tenapanor should be discontinued.(1)
DISCUSSION: In clinical trials, 43-53% of CKD patients on dialysis treated with tenapanor developed diarrhea. Diarrhea usually occurred soon after treatment initiation and was severe in 5% of patients.(1)
Moderate Interaction: Assess the risk to the patient and take action as needed.
Mineral Oil/Paricalcitol
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: Mineral oil may impair intestinal absorption of fat-soluble vitamins. Paricalcitol is an analogue of a fat-soluble vitamin and therefore mineral oil may interfere with absorption of paricalcitol.(1)
CLINICAL EFFECTS: Concurrent use may result in decreased levels and clinical effects of paricalcitol.(1)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: The US manufacturer of paricalcitol capsules recommends that paricalcitol be taken at least 1 hour before or 4-6 hours after taking mineral oil.(1)
DISCUSSION: The manufacturer recommends that administration of paricalcitol capsules be separated from concurrent administration with drugs that impair intestinal absorption of fat-soluble vitamins.(1)
Contraindications
There is no enhanced messaging for this drug.
- Bed-ridden
- Gastrointestinal obstruction
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
Less Frequent
- Perianal irritation
- Pruritus ani
Precautions
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
ICD codes
| Code | Type | Description |
|---|---|---|
| Constipation | ||
| K59.0 | ICD10CM | Constipation |
| K59.00 | ICD10CM | Constipation, unspecified |
| K59.01 | ICD10CM | Slow transit constipation |
| K59.03 | ICD10CM | Drug induced constipation |
| K59.04 | ICD10CM | Chronic idiopathic constipation |
| K59.09 | ICD10CM | Other constipation |
ICD code information from First Databank (FDB).
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.